In this PiPCast™, we discuss whether a patent inventor must be human or can include artificial intelligence systems in Australia, and look to the future legal developments in this space.
BioBlast® w/e 26 Aug 22: Novartis to spin off Sandoz, Moderna sues Pfizer and BioNTech over COVID vaccine, Amgen’s eculizumab, Alvotech’s denosumab, Samsung Bioepis’ ranibizumab, Formycon’s ranibizumab, JAMP’s CA win against AbbVie
Significant biosimilar activities this week include: 23 Aug 22 | Amgen announces the results of Ph III eculizumab trials Amgen announced the results of a Ph III study evaluating...
High Court has a bet each way on electronic gaming machine patent
Aristocrat Technologies Australia Pty Ltd v Commissioner of Patents [2022] HCA 29Date:Court:Judges:17 June 2022High Court of AustraliaKiefel CJ, Gageler, Keane, Gordon, Edelman...
High Court has a bet each way on electronic gaming machine patent
Even the High Court of Australia could not come to a majority decision on the thorny question of the patentability of computer-implemented inventions in its highly anticipated...
BioBlast® w/e 19 August 2022: J&J Remicade decline, ALX evorpacept, FDA approves 100mg/mL Hadlima™, Formycon Ph III ustekinumab trials, Beovu® additional indication, EC approves Vegzelma™, Fresenius Kabi tocilizumab, Cipla pegfilgrastim, Merck/Orna Therapeutics collaboration
Significant biosimilar activities this week include: 11 Aug 22 | ALX Oncology initiates Ph II trials of evorpacept in combination with cetuximab and pembrolizumab ALX Oncology...
BioBlast® w/e 12 August 2022: Mylan Eylea® IPR, Daiichi Sankyo trastuzumab deruxtecan, Alvotech Icelandic listing move, Opthea funding for OPT-302, Merck Keytruda® clinical trials, Qila denosumab study
Significant biosimilar activities this week include: 27 Jul 22 | CN | Ph III trial shows Qila’s denosumab biosimilar improves bone mineral density It has been reported that a Ph...
BioBlast® w/e 05 August 2022: Viatris’ etanercept; Celltrion’s seeks IC for Yuflyma®; Samsung Bioepis’ 3rd AU suit against Fresenius Kabi; AbbVie’s patent thicket; New Stelara® indication; Fresenius Kabi’s tocilizumab; Coherus’ ranibizumab US approved with IC; Regeneron sues Viatris (aflibercept); Coherus’ high concentration adalimumab
Significant biosimilar activities this week include: 27 Jul 22 | AU | Viatris (Mylan) seeks PBS listing for etanercept biosimilar Alphapharm (Viatris’ Australian subsidiary) has...
Medicinal Cannabis in Australia | Part 6: What’s in a name – Trade mark protection for MC strains
In the field of medicinal cannabis, plant varietal or cultivar names that are protected by a registered right such as a PBR (plant breeder right) are often mirrored in commercial...
PiPCast™ | PTE in Australia
Pearce IP’s Naomi Pearce speaks about the hot topic in Australian patent law: Patent Term Extension (PTE) in Australia
The Rise and Rise of CAR-T cell therapy and the Future of Patent Disputes in Australia
Chimeric Antigen Receptor (CAR)-T cell therapy is a pioneering technology that is successfully changing the way we think about the treatment of cancer, in particular blood...
Bringing home the bacon – or are you?
Introduction Plant based protein products are already a well established destination in the supermarket aisle. Australia is reportedly the third fastest growing market for such...
BioBlast® w/e 29 July 2022: FDA approves Sandoz’s natalizumab, TGA approves Henlius/Cipla trastuzumab, Prestige/Intas bevacizumab deal, Biocon biosimilars revenue up
Significant biosimilar activities this week include: 25 Jul 22 | US | FDA accepts ABLA for natalizumab biosimilar Sandoz announced that the FDA has accepted its ABLA for a...
Pearce IP and its CEO feature in shortlist for Women in Business Law Awards APAC 2022
We are proud to announce that Pearce IP and its CEO have been shortlisted for three awards at the APAC 2022 Women in Business Law Awards, with the winners to be announced on...
Pearce recognised as one of the Australasian Lawyer’s Most Influential Lawyers for 2022
With great pleasure, we announce that our CEO and Executive Lawyer, Patent Attorney and Trade Mark Attorney Naomi Pearce has been named as one of the Australasian Lawyer’s Most...
Full Court dismisses Boehringer appeal on obviousness of veterinary injectable formulation
The Full Court’s decision in Boehringer Ingelheim Animal Health USA Inc., v Intervet International B.V. [2022] FCAFC 88 is a useful analysis of the application of the “Cripps...
BioBlast® w/e 22 July 2022: Hikma/Celltrion adalimumab deal, Erasca/Lilly cetuximab clinical supply agreement, Celltrion’s tocilizumab clinical trial, Alvotech denosumab study, 100mg/mL Hyrimoz® adalimumab sBLA and Novartis/Sandoz update
18 Jul 22 | MENA | Hikma and Celltrion enter into commercialisation agreement for YuflymaTM Hikma Pharmaceuticals announced that it has entered into a commercialisation agreement...
“Sketchy” prior art renders Globaltech device patent not obvious
Globaltech Corporation Pty Ltd v Reflex Instruments Asia Pacific Pty Ltd [2022] FCA 797Date:Court:Judge:12 July 2022Federal Court of AustraliaJagot JBackground Globaltech...
BioBlast® w/e 15 July 2022: Alvotech board expansion, [vic-]trastuzumab duocarmazine BLA accepted, second Zylonta® + rituximab DLBCL trials, Polpharma natalizumab MAA and eight-year Perjeta® data
11 Jul 22 | Overland ADCT commences trials of Zynlonta® in combination with rituximab in DLBCL Overland ADCT BioPharma announced the dosing of the first patient in China in its...
WTO Members endorse latest COVID IP waiver draft
The key terms of an updated draft covid IP waiver have been released by the WTO. The draft includes terms intended to alleviate concerns of developed countries. However it will...
Pearce IP celebrates milestone birthday and firm and individual rankings in IAM Patent 1000 2022
This week Pearce IP celebrated its 5th birthday, and received glowing reviews and rankings for the firm, and for three of its individual patent professionals by IAM Patent 1000....
BioBlast® w/e 8 July 2022: featuring Xbrane’s ranibizumab BLA, Viatris’ insulin glargine, Alvotech’s aflibercept study and AU’s July PBAC meeting
04 Jul 22 | US | Xbrane Biopharma provides update on ranibizumab biosimilar Xbrane Biopharma confirmed that it will resubmit a BLA for its biosimilar to Lucentis® (ranibizumab)...
Pearce IP Prosecution Team Listed in MIP IP Stars
Pearce IP is proud to announce that our prosecution team has also been ranked among the best in Australia by Managing IP. This is in addition to the individual rankings of...
BioBlast® w/e 01 July 22: Samsung seeks to revoke Fresenius’ AU adalimumab patent, Daiichi Sankyo’s trastuzumab deruxtecan sNDA submitted in Japan, PDS0101 Fast-tracked in US, Henlius HLX53 IND accepted
24 Jun 22 | AU | Samsung Bioepis commences AU revocation action against Fresenius Kabi adalimumab patent Samsung Bioepis filed a suit against Fresenius Kabi in the AU Federal...
Pearce IP named as Finalist for Intellectual Property Team of the Year – Australian Law Awards 2022
We are proud to announce that the Pearce IP team of patent and trademark lawyers and attorneys has been selected as a finalist for the Lawyers Weekly Intellectual Property Team...
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.